BOTULINUM TOXIN IN PATIENTS WITH SPASTIC PARAPARESIA ASSOCIATED WITH ESCLEROSIS MULTIPLE
What it found
No result yet.
What was tested
Treatment tested
- Botulinum toxin type a
Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme
What it measured
Main measures
- Change from baseline observed in the maximum distance that a patient can walk in 6 minutes (6MWT) at 4 weeks after each infiltration.
Walking and mobility
Other measures (1)
- Change observed in the total score of the EDSS scale before and after the application of the treatment.
Disability progression
Who could take part
MS (type not specified)
Inclusion: - Acceptance and signature of informed consent. Exclusion: - Psychiatric illness that hinders participation in the trial.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
To assess the effectiveness of repeated TXB infiltrations on gait in patients with Multiple Sclerosis who presented limb spasticity less than 4 weeks after infiltration and its maintenance over time at 12 months, using objective results obtained by the clinician (6MWT ) and reported by the patient (MSWS-12).
Loading reviews and guidelines…
Related trials
- ICE Trial
Phase 4 · Ongoing (inferred)
Still running
- A Study to Investigate Arbaclofen ER Tablets for the Trea…
Phase 3 · Not yet recruiting
Still running
- Cannabis (THC vs. CBD) in Multiple Sclerosis
Phase 2 · Recruiting
Still running
- ICE
Phase 4 · Recruiting
Still running
- Mechanisms of Cannabidiol in Persons With MS: the Role of…
Phase 2 · Recruiting
Still running
- AntibioBoNTA
Phase 3 · Ongoing
Still running
History
Started
Sept 2018
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error